Dear Editor:

We read with interest the article by Al Jaberi et al. about a 13-year-old male who developed progressive quadruparesis 2 weeks after a mild SARS-CoV-2 infection that did not require hospitalisation [1]. Only 4 weeks after onset of the neurological manifestations was there a neurological evaluation of suspected SARS-CoV-2 associated Guillain–Barre syndrome (GBS), which led to the diagnosis of acute, inflammatory demyelinating polyneuropathy (AIDP) [1]. The patient benefited from intravenous immunoglobulins (IVIG) [1]. The study is appealing but raises concerns that need to be discussed.

We disagree with the presentation that cerebral and spinal magnetic resonance imaging (MRI) was probably normal due to steroid use a few days before imaging [1]. Since steroids are often ineffective in GBS [2], enhancing nerve roots should have been visible despite application of steroids. Contrast-enhanced spinal MRI may have been unremarkable in the index case due to the 4-week latency period between the onset of clinical neurologic manifestations and imaging studies.

We should be told why the diagnosis was delayed by 4 weeks. The patient presented to the emergency department two weeks after onset of COVID-19 with progressive, ascending weakness [1]. Such a clinical picture in a child or adult should ring the alarm bells and lead to immediate clarification of the abnormalities. The delay in diagnosis and therapy of GBS has been shown to be responsible for the increased mortality of the disease [3].

It should be reported whether the patient has been tested for SARS-CoV-2 by PCR test 14 days after the episode of fever, coughing, and runny nose. The PCR should already have been positive at the onset of the neurological abnormalities.

The serum titre of neutralising IgG anti-SARS-CoV-2 antibodies and its reference limits for the detection of the infection should be communicated to us.

We should be informed about the rationale for applying steroids together with intravenous immunoglobulins (IVIG) [1]. Steroids are usually ineffective for GBS [4].

We should be informed about the indication for steroids “a few days before the MRI”.

Overall, the interesting study has limitations that call the results and their interpretation into question. Clarifying these weaknesses would strengthen the conclusions and could improve the study. Patients with progressive, ascending quadruparesis should be taken seriously and promptly evaluated neurologically, especially given that GBS can complicate both SARS-CoV-2 infections and anti-SARS-CoV-2 vaccination. Delaying the diagnosis and treatment can worsen the outcome.